Abbvie Inc
ABBV
Market Cap$291.55B
Close$
Earnings Call Q4 2023
February 2, 2024 - AI Summary
AbbVie reported strong fourth quarter and full-year 2023 results, with revenues exceeding expectations and growth in the base business excluding Humira.
The company's growth platform, which includes Skyrizi, Rinvoq, Vraylar, Ubrelvy, and Qulipta, delivered double-digit sales growth in 2023 and is expected to continue driving growth in 2024.
AbbVie reaffirmed its long-term sales outlook, including a return to robust revenue growth in 2025 and a high single-digit CAGR through the end of the decade.
Exclusive for Stockcircle Pro members
Sign up
$175.52
4.6% upside
Current Fair Value
4.6% upsideUndervalued by 4.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $291.55 Billion |
|---|---|
| Enterprise Value | $338.12 Billion |
| Dividend Yield | $5.9761 (3.63%) |
| Earnings per Share | $2.72 |
| Beta | 0.25 |
| Outstanding Shares | 1,770,646,983 |
| Avg 30 Day Volume | 5,265,037 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 60.49 |
|---|---|
| PEG | -90.11 |
| Price to Sales | 5.59 |
| Price to Book Ratio | 33.56 |
| Enterprise Value to Revenue | 6.22 |
| Enterprise Value to EBIT | 25.32 |
| Enterprise Value to Net Income | 70 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 5.73 |
Revenue Sources
No data
ESG Score
No data
About Abbvie Inc
CEO: Richard Gonzalez